Remove barriers to clinical research for schedule 1 drugs with therapeutic potential
Leslie A. King, David Nutt, David E. Nichols
BMJ May 2, 2023 DOI: 10.1136/bmj.p981 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Keywords | Schedule Intensive care medicine Pharmacology |
| Citations | 1 |
| Key points | Argues that the regulation of clinical research on schedule 1 drugs with therapeutic potential should be reviewed. |
Abstract
Regulation of clinical research on schedule 1 drugs with therapeutic potential should be reviewed, argue Leslie King, David Nutt and David Nichols
Citations in the library
Cites 4
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- The Therapeutic Potential of Psilocybin in Alcohol Use Disorder Recovery: A Literature Review Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal January 5, 2023
- Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature reviews. Neuroscience June 12, 2013